|
Gene: SUCLG1 |
Gene summary for SUCLG1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SUCLG1 | Gene ID | 8802 |
Gene name | succinate-CoA ligase GDP/ADP-forming subunit alpha | |
Gene Alias | GALPHA | |
Cytomap | 2p11.2 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | P53597 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8802 | SUCLG1 | C08 | Human | Oral cavity | OSCC | 1.39e-68 | 1.54e+00 | 0.1919 |
8802 | SUCLG1 | C09 | Human | Oral cavity | OSCC | 1.51e-07 | 4.09e-01 | 0.1431 |
8802 | SUCLG1 | LN22 | Human | Oral cavity | OSCC | 4.03e-10 | 1.42e+00 | 0.1733 |
8802 | SUCLG1 | LN38 | Human | Oral cavity | OSCC | 4.51e-08 | 1.37e+00 | 0.168 |
8802 | SUCLG1 | LN46 | Human | Oral cavity | OSCC | 1.46e-24 | 1.11e+00 | 0.1666 |
8802 | SUCLG1 | LP15 | Human | Oral cavity | LP | 1.21e-05 | 1.14e+00 | 0.2174 |
8802 | SUCLG1 | LP17 | Human | Oral cavity | LP | 1.14e-02 | 8.68e-01 | 0.2349 |
8802 | SUCLG1 | SYSMH1 | Human | Oral cavity | OSCC | 2.32e-13 | 4.30e-01 | 0.1127 |
8802 | SUCLG1 | SYSMH2 | Human | Oral cavity | OSCC | 1.60e-29 | 1.20e+00 | 0.2326 |
8802 | SUCLG1 | SYSMH3 | Human | Oral cavity | OSCC | 2.34e-32 | 1.12e+00 | 0.2442 |
8802 | SUCLG1 | SYSMH4 | Human | Oral cavity | OSCC | 1.60e-07 | 2.41e-01 | 0.1226 |
8802 | SUCLG1 | SYSMH5 | Human | Oral cavity | OSCC | 2.72e-08 | 3.71e-01 | 0.0647 |
8802 | SUCLG1 | SYSMH6 | Human | Oral cavity | OSCC | 2.26e-19 | 7.46e-01 | 0.1275 |
8802 | SUCLG1 | P2_S3_AK | Human | Skin | AK | 9.22e-04 | 1.69e-01 | -0.3287 |
8802 | SUCLG1 | P4_S8_cSCC | Human | Skin | cSCC | 4.29e-17 | 2.37e-01 | -0.3095 |
8802 | SUCLG1 | P5_S10_cSCC | Human | Skin | cSCC | 8.23e-06 | 9.18e-02 | -0.299 |
8802 | SUCLG1 | P1_cSCC | Human | Skin | cSCC | 5.32e-38 | 1.21e+00 | 0.0292 |
8802 | SUCLG1 | P2_cSCC | Human | Skin | cSCC | 4.12e-36 | 9.15e-01 | -0.024 |
8802 | SUCLG1 | P4_cSCC | Human | Skin | cSCC | 8.89e-43 | 1.02e+00 | -0.00290000000000005 |
8802 | SUCLG1 | P10_cSCC | Human | Skin | cSCC | 4.92e-34 | 1.03e+00 | 0.1017 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0009060 | Colorectum | AD | aerobic respiration | 108/3918 | 189/18723 | 9.14e-28 | 1.43e-24 | 108 |
GO:0045333 | Colorectum | AD | cellular respiration | 119/3918 | 230/18723 | 3.21e-25 | 4.02e-22 | 119 |
GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
GO:0006099 | Colorectum | AD | tricarboxylic acid cycle | 19/3918 | 30/18723 | 5.82e-07 | 2.09e-05 | 19 |
GO:00090601 | Colorectum | SER | aerobic respiration | 96/2897 | 189/18723 | 5.53e-30 | 1.70e-26 | 96 |
GO:00453331 | Colorectum | SER | cellular respiration | 103/2897 | 230/18723 | 2.35e-26 | 3.61e-23 | 103 |
GO:00060911 | Colorectum | SER | generation of precursor metabolites and energy | 168/2897 | 490/18723 | 1.39e-25 | 1.70e-22 | 168 |
GO:00159801 | Colorectum | SER | energy derivation by oxidation of organic compounds | 119/2897 | 318/18723 | 5.28e-22 | 4.62e-19 | 119 |
GO:00060991 | Colorectum | SER | tricarboxylic acid cycle | 15/2897 | 30/18723 | 1.02e-05 | 3.34e-04 | 15 |
GO:00090602 | Colorectum | MSS | aerobic respiration | 98/3467 | 189/18723 | 3.35e-25 | 1.05e-21 | 98 |
GO:00060912 | Colorectum | MSS | generation of precursor metabolites and energy | 186/3467 | 490/18723 | 1.14e-24 | 2.15e-21 | 186 |
GO:00453332 | Colorectum | MSS | cellular respiration | 107/3467 | 230/18723 | 1.64e-22 | 2.05e-19 | 107 |
GO:00159802 | Colorectum | MSS | energy derivation by oxidation of organic compounds | 131/3467 | 318/18723 | 2.60e-21 | 2.70e-18 | 131 |
GO:00060992 | Colorectum | MSS | tricarboxylic acid cycle | 16/3467 | 30/18723 | 1.90e-05 | 4.12e-04 | 16 |
GO:00060914 | Colorectum | FAP | generation of precursor metabolites and energy | 128/2622 | 490/18723 | 5.58e-13 | 4.28e-10 | 128 |
GO:00159804 | Colorectum | FAP | energy derivation by oxidation of organic compounds | 85/2622 | 318/18723 | 1.36e-09 | 2.77e-07 | 85 |
GO:00090604 | Colorectum | FAP | aerobic respiration | 57/2622 | 189/18723 | 7.02e-09 | 1.02e-06 | 57 |
GO:00453334 | Colorectum | FAP | cellular respiration | 65/2622 | 230/18723 | 1.13e-08 | 1.33e-06 | 65 |
GO:00060993 | Colorectum | FAP | tricarboxylic acid cycle | 13/2622 | 30/18723 | 8.95e-05 | 1.58e-03 | 13 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa012001 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa000202 | Colorectum | SER | Citrate cycle (TCA cycle) | 16/1580 | 30/8465 | 2.06e-05 | 2.74e-04 | 1.99e-04 | 16 |
hsa012002 | Colorectum | SER | Carbon metabolism | 40/1580 | 115/8465 | 2.77e-05 | 3.41e-04 | 2.47e-04 | 40 |
hsa006402 | Colorectum | SER | Propanoate metabolism | 13/1580 | 32/8465 | 3.20e-03 | 2.12e-02 | 1.54e-02 | 13 |
hsa000203 | Colorectum | SER | Citrate cycle (TCA cycle) | 16/1580 | 30/8465 | 2.06e-05 | 2.74e-04 | 1.99e-04 | 16 |
hsa012003 | Colorectum | SER | Carbon metabolism | 40/1580 | 115/8465 | 2.77e-05 | 3.41e-04 | 2.47e-04 | 40 |
hsa006403 | Colorectum | SER | Propanoate metabolism | 13/1580 | 32/8465 | 3.20e-03 | 2.12e-02 | 1.54e-02 | 13 |
hsa012004 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
hsa000204 | Colorectum | MSS | Citrate cycle (TCA cycle) | 16/1875 | 30/8465 | 1.84e-04 | 1.47e-03 | 9.00e-04 | 16 |
hsa006404 | Colorectum | MSS | Propanoate metabolism | 15/1875 | 32/8465 | 1.68e-03 | 9.05e-03 | 5.55e-03 | 15 |
hsa012005 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
hsa000205 | Colorectum | MSS | Citrate cycle (TCA cycle) | 16/1875 | 30/8465 | 1.84e-04 | 1.47e-03 | 9.00e-04 | 16 |
hsa006405 | Colorectum | MSS | Propanoate metabolism | 15/1875 | 32/8465 | 1.68e-03 | 9.05e-03 | 5.55e-03 | 15 |
hsa012006 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
hsa006406 | Colorectum | FAP | Propanoate metabolism | 15/1404 | 32/8465 | 6.21e-05 | 6.10e-04 | 3.71e-04 | 15 |
hsa000206 | Colorectum | FAP | Citrate cycle (TCA cycle) | 14/1404 | 30/8465 | 1.16e-04 | 1.02e-03 | 6.21e-04 | 14 |
hsa012007 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
hsa006407 | Colorectum | FAP | Propanoate metabolism | 15/1404 | 32/8465 | 6.21e-05 | 6.10e-04 | 3.71e-04 | 15 |
hsa000207 | Colorectum | FAP | Citrate cycle (TCA cycle) | 14/1404 | 30/8465 | 1.16e-04 | 1.02e-03 | 6.21e-04 | 14 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
SUCLG1 | BAS | Cervix | Healthy | GIPC1,DNAAF5,COX5A, etc. | 2.36e-01 |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SUCLG1 | SNV | Missense_Mutation | novel | c.968T>G | p.Val323Gly | p.V323G | P53597 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SUCLG1 | SNV | Missense_Mutation | novel | c.793A>G | p.Asn265Asp | p.N265D | P53597 | protein_coding | tolerated(0.84) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SUCLG1 | SNV | Missense_Mutation | novel | c.487G>A | p.Glu163Lys | p.E163K | P53597 | protein_coding | tolerated(0.09) | benign(0.001) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
SUCLG1 | SNV | Missense_Mutation | rs145106503 | c.721G>A | p.Glu241Lys | p.E241K | P53597 | protein_coding | tolerated(0.39) | benign(0.081) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SUCLG1 | SNV | Missense_Mutation | c.13C>A | p.Leu5Ile | p.L5I | P53597 | protein_coding | deleterious_low_confidence(0.05) | benign(0.001) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SUCLG1 | SNV | Missense_Mutation | novel | c.904N>A | p.Ala302Thr | p.A302T | P53597 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
SUCLG1 | SNV | Missense_Mutation | rs145106503 | c.721G>A | p.Glu241Lys | p.E241K | P53597 | protein_coding | tolerated(0.39) | benign(0.081) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
SUCLG1 | SNV | Missense_Mutation | novel | c.319G>A | p.Ala107Thr | p.A107T | P53597 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SUCLG1 | SNV | Missense_Mutation | novel | c.216N>A | p.Ser72Arg | p.S72R | P53597 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SUCLG1 | SNV | Missense_Mutation | novel | c.393N>C | p.Glu131Asp | p.E131D | P53597 | protein_coding | tolerated(0.06) | benign(0.131) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |